Patents Assigned to The Trustees of the University of Pennsylvania
  • Publication number: 20240082361
    Abstract: This invention relates to methods of treating and ameliorating congenital and neonatal hyperinsulinism and post-prandial hypoglycemia, comprising the step of administering an antagonist of the Glucagon-Like Peptide-1 (GLP-1) receptor, e.g. a GLP-1 fragment or analogue thereof.
    Type: Application
    Filed: February 14, 2023
    Publication date: March 14, 2024
    Applicants: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, The Children's Hospital of Philadelphia
    Inventors: Doris STOFFERS, Diva D. DE LEON, Charles STANLEY
  • Patent number: 11925466
    Abstract: An electrode, the electrode including an exposed contact surface, the exposed surface comprising a contact material, the contact material comprising a MXene. A device, the device including a plurality of electrodes, each of the plurality of electrodes comprising an exposed contact surface, the exposed surface comprising a contact material, the contact material comprising a MXene. A method, the method including delivering electrical stimulation to a subject with an electrode that comprises an exposed contact surface, the exposed contact surface comprising a contact material that includes a MXene.
    Type: Grant
    Filed: September 14, 2018
    Date of Patent: March 12, 2024
    Assignees: The Trustees of the University of Pennsylvania, Drexel University
    Inventors: Flavia Vitale, Brian Litt, Nicolette Driscoll, Yury Gogotsi, Babak Anasori, Kathleen Maleski
  • Patent number: 11925685
    Abstract: Disclosed herein is a composition comprising a recombinant nucleic acid sequence that encodes an antibody to a Zika viral antigen, and functional fragments thereof. The invention also relates to a composition comprising the combination of a first composition that elicits an immune response in a mammal against zika virus and a second composition comprising a recombinant nucleic acid sequence encoding an antibody, a fragment thereof, a variant thereof, or a combination thereof. In some instances, the nucleic acid molecule comprises a nucleotide sequence encoding an anti-ZIKV-Envelope (anti-ZIKV E) Protein antibody.
    Type: Grant
    Filed: September 19, 2017
    Date of Patent: March 12, 2024
    Assignees: The Trustees of the University of Pennsylvania, Inovio Pharmaceuticals, Inc., The Wistar Institute of Anatomy and Biology
    Inventors: David Weiner, Karuppiah Muthumani, Jian Yan
  • Patent number: 11925662
    Abstract: The present invention relates to compositions and methods that provide novel anti-tumor therapies in cancer. In one aspect, the present invention features a hybrid neutrophil in a non-naturally occurring container, wherein the hybrid neutrophil expresses at least one neutrophil associated molecule selected from the group consisting of: Arg1, MPO, CD66b, and CD15, and at least one antigen-presenting cell (APC) associated molecule selected from the group consisting of: CD14, HLA-DR, CD32, CD64, and CD89. In another aspect, the present invention features methods of generating a hybrid neutrophil. In still another aspect, the present invention features methods of inhibiting tumor growth in a subject, treating a tumor in a subject, and increasing efficacy of an antibody against a tumor in a subject. The methods comprise (a) administering to the subject an effective amount of an anti-tumor antibody and (b) administering to or generating in the subject an effective amount of a hybrid neutrophil.
    Type: Grant
    Filed: December 15, 2020
    Date of Patent: March 12, 2024
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Evgeniy Eruslanov, Steven Albelda
  • Patent number: 11918586
    Abstract: The present invention is relates to a compound of formula (I), wherein X1, X2 and X3 are, independently of each other, N or CH; with the proviso that at least two of X1 X2 and X3 are N; Y is N or CH; W is H or F; with the proviso that when W is F, then X1, X2 and X3 are N; R1 and R2 are independently of each other (i) a morpholinyl of formula (II) wherein the arrow denotes the bond in formula (I); and wherein R3 and R4 are independently of each other H, C1-C3alkyl optionally substituted with one or two OH, C1-C2fluoroalkyl, C1-C2alkoxy, C1alkoxyC1-C3alkyl, CN, or C(O)O—C1-C2alkyl; or R3 and R4 form together a bivalent residue —R5R6— selected from C1-C3alkylene optionally substituted with 1 to 4 F, —CH2—O—CH2—, —CH2—NH—CH2—, or any of the structures wherein the arrows denote the bonds in formula (II); or (ii) a saturated 6-membered heterocyclic ring Z selected from thiomorpholinyl and piperazinyl, optionally substituted by 1 to 3 R7; wherein R7 is independently at each occurrence C1-C3alkyl optionally substitu
    Type: Grant
    Filed: March 26, 2021
    Date of Patent: March 5, 2024
    Assignees: TORQUR AG, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Doriano Fabbro, Paul Hebeisen, Petra Hillmann-Wuellner, Anton Stuetz, John T. Seykora, Florent Beaufils
  • Patent number: 11919946
    Abstract: The present invention provides compositions and methods for regulating the specificity and activity of T cells. In one embodiment, the invention provides a type of chimeric antigen receptor (CAR) wherein the CAR is termed a “KIR-CAR” which is a CAR design comprising a component of a receptor naturally found on natural killer (NK) cells. In one embodiment, the NK receptor includes but is not limited to a naturally occurring activating and inhibitory receptor of NK cells known as a killer cell immunoglobulin-like receptor (KIR).
    Type: Grant
    Filed: April 1, 2020
    Date of Patent: March 5, 2024
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Michael C. Milone, Enxiu Wang
  • Patent number: 11920130
    Abstract: The present disclosure provides gene edited modified immune cells or precursors thereof (e.g., gene edited modified T cells) comprising an exogenous T cell receptor (TCR) and/or a chimeric antigen receptor (CAR) having specificity for a target antigen, and an insertion and/or deletion in one or more endogenous gene loci, wherein the endogenous gene loci encode regulators of T cell function, thereby resulting in immune cells having enhanced function. Compositions and methods of treatment are also provided. The present invention provides methods of screening for TCR- or CAR-T cells with enhanced immune function (e.g., T cell efficacy, T cell memory, and/or T cell persistence).
    Type: Grant
    Filed: May 12, 2022
    Date of Patent: March 5, 2024
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Yangbing Zhao, Jiangtao Ren
  • Patent number: 11920116
    Abstract: The presently disclosed subject matter provides systems and methods for producing a three-dimensional model of a human cervix. A microdevice is provided for culturing human cervical cells. The microdevice can include an upper microchannel including live ectocervical epithelial cells. The microdevice can include a lower microchannel including a first parallel lane and a second parallel lane including stromal media. The first and the second parallel lanes can be lined with live vascular endothelial cells. The lower microchannel can include a third parallel lane including uterine fibroblasts and live smooth muscle cells embedded in hydrogel. The first, second, and third lanes of the lower microchannel can be separated by protrusion structures. The third parallel lane can be positioned in the lower microchannel in between the first and the second parallel lanes. The microdevice can further include a porous membrane positioned in between the upper microchannel and the lower microchannel.
    Type: Grant
    Filed: June 18, 2021
    Date of Patent: March 5, 2024
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Dongeun Huh, Jeongyun Seo
  • Patent number: 11923908
    Abstract: Provided are methods for optical communication, comprising: generating a phase difference signal with heterodyne or homodyne phase-locked-loop (PLL) from between an optical input signal and a local laser source; controlling the local laser source with the phase difference signal; demodulating the optical input signal using the local laser source as a carrier signal to generate a baseband output signal; and controlling the heterodyne or homodyne PLL and the demodulation with an electrical oscillator signal. Also provided are related methods.
    Type: Grant
    Filed: March 18, 2022
    Date of Patent: March 5, 2024
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Firooz Aflatouni, Zhe Xuan
  • Publication number: 20240067948
    Abstract: The present invention includes mutant AID, APOBEC, and Tet enzymes with improved functions. In one aspect the invention provides APOBEC fusion proteins comprising hyperactive deamination activity. In another aspect, the invention provides AID mutant proteins comprising hyperactive deamination activity. In yet another aspect, the invention provides mutant Tet proteins capable of stalling oxidation at a 5-hydroxymethylcytosine (hmC).
    Type: Application
    Filed: April 5, 2023
    Publication date: February 29, 2024
    Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Rahul Kohli, Emily Schutsky, Monica Yun Liu
  • Patent number: 11913026
    Abstract: A bispecific cytotoxic lymphocyte or macrophage-redirecting autoantibody comprising a cytotoxic lymphocyte or macrophage targeting domain and an autoantibody. Methods for producing bispecific cytotoxic lymphocyte or macrophage-redirecting autoantibody comprising a cytotoxic lymphocyte or macrophage targeting domain and an autoantibody. Methods for treating a subject in need thereof comprising administering to the subject an isolated bispecific cytotoxic lymphocyte or macrophage-redirecting autoantibody.
    Type: Grant
    Filed: March 17, 2020
    Date of Patent: February 27, 2024
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Andrew Tsourkas, James Z. Hui, Burcin Altun, Fabiana Zappala
  • Patent number: 11913963
    Abstract: The present invention provides a humanized antibody or antibody fragment comprising (a) a humanized light chain comprising 1) Complementarity Determining Region (CDR)-L1, the sequence of which is identical to the sequence of SEQ ID NO: 3; 2) CDR-L2, the sequence of which is identical to the sequence of SEQ ID NO: 4; and 3) CDR-L3, the sequence of which is identical to the sequence of SEQ ID NO: 5, and (b) a humanized heavy chain comprising 1) CDR-H1, the sequence of which is identical to the sequence of SEQ ID NO: 6; 2) CDR-H2, the sequence of which is identical to the sequence of SEQ ID NO: 7; and 3) CDR-H3, the sequence of which is identical to the sequence of SEQ ID NO: 8, as well as methods for treating, diagnosing, and monitoring the progression of HIT. The present invention also provides methods for assessing the antigenicity and ability to cause HIT of anionic anticoagulants.
    Type: Grant
    Filed: September 2, 2022
    Date of Patent: February 27, 2024
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Mark I. Greene, Douglas B. Cines, Zheng Cai, Zhiqiang Zhu
  • Patent number: 11912753
    Abstract: The invention provides compositions and methods for adoptive T cell therapy in treating a variety of disorders including cancer, infections, and autoimmune disorders. In one embodiment, the invention provides a universal immune receptor (UnivIR) that comprises an extracellular label binding domain, a transmembrane domain, and a cytoplasmic domain or otherwise an intracellular domain.
    Type: Grant
    Filed: June 21, 2021
    Date of Patent: February 27, 2024
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Nathalie Scholler, Katarzyna Urbanska, Daniel J. Powell, Jr.
  • Patent number: 11905321
    Abstract: The invention includes a chimeric autoantibody receptor (CAAR) specific for anti-muscle-specific kinase (MuSK) B cell receptor (BCR), compositions comprising the CAAR, polynucleotides encoding the CAAR, vectors comprising a polynucleotide encoding the CAAR, and recombinant cells comprising the CAAR.
    Type: Grant
    Filed: June 4, 2019
    Date of Patent: February 20, 2024
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Aimee S. Payne, Christoph T. Ellebrecht, Sangwook Oh, Michael C. Milone
  • Patent number: 11903929
    Abstract: The present invention concerns the use of compounds and compositions for the treatment or prevention of Flavivirus infections, such as dengue virus infections and Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as dengue virus and Zika virus infection, by administering a compound or composition of the invention, to a subject in need thereof; methods for inhibiting Flavivirus infections, such as dengue virus and Zika virus infections, in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits useful for treating or preventing Flavivirus infections, such as dengue virus and Zika virus infections.
    Type: Grant
    Filed: June 28, 2022
    Date of Patent: February 20, 2024
    Assignees: Florida State University Research Foundation, Inc., The Unites States of America, as represented by the Secretary Department of Health and Human Services, The Trustees of the University of Pennsylvania
    Inventors: Hengli Tang, Emily M. Lee, Wei Zheng, Ruili Huang, Miao Xu, Wenwei Huang, Khalida Shamim, Guoli Ming, Hongjun Song
  • Patent number: 11906511
    Abstract: The present invention provides compositions and methods for detecting exhausted T cells in a subject. The present invention also provides methods for treating a subject having a disease characterized by the presence of exhausted T cells or certain subpopulations thereof.
    Type: Grant
    Filed: October 26, 2018
    Date of Patent: February 20, 2024
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: E. John Wherry, Bertram Bengsch, Omar Khan, Jennifer Wu, Josephine Giles
  • Publication number: 20240050186
    Abstract: Devices and methods for stereotactic placement of a catheter are disclosed herein. The device can include a conical component comprising a first opening and a second opening, a cylindrical rod for receiving the catheter, a footplate for securing the device underneath a skin of a subject, and a clip for holding the catheter. The first opening and second opening can form a lumen therethrough. The cylindrical rod can be coupled to the first opening, and the footplate can be coupled to the conical component.
    Type: Application
    Filed: October 26, 2023
    Publication date: February 15, 2024
    Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Rachel BLUE, Michael SPADOLA
  • Patent number: 11897845
    Abstract: Provided is a compound of formula (I) in which Ar1, R1, U, V, W, X, and p are as described herein. Also provided are methods of using a compound of formula (I), including a method of treating cancer, a method of treating a patient with cancer cells resistant to an anti-cancer agent, and a method of inhibiting lactate dehydrogenase A (LDHA) and/or lactate dehydrogenase B (LDHB) activity in a cell.
    Type: Grant
    Filed: January 10, 2022
    Date of Patent: February 13, 2024
    Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, VANDERBILT UNIVERSITY, THE UAB RESEARCH FOUNDATION, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: David J. Maloney, Alex Gregory Waterson, Ganesh Rai Bantukallu, Kyle Ryan Brimacombe, Plamen Christov, Chi V. Dang, Victor Darley-Usmar, Xin Hu, Ajit Jadhav, Somnath Jana, Kwangho Kim, Jennifer L. Kouznetsova, William J. Moore, Bryan T. Mott, Leonard M. Neckers, Anton Simeonov, Gary Allen Sulikowski, Daniel Jason Urban, Shyh Ming Yang
  • Patent number: 11896654
    Abstract: Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody or fragment thereof that targets an immune checkpoint molecule. The disclosure also provides a method of preventing and/or treating disease in a subject using said composition and method of generation.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: February 13, 2024
    Assignees: The Trustees of the University of Pennsylvania, The Wistar Institute of Anatomy and Biology, Inovio Pharmaceuticals
    Inventors: David B. Weiner, Kar Muthumani, Niranjan Sardesai
  • Patent number: RE49847
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.
    Type: Grant
    Filed: January 5, 2022
    Date of Patent: February 27, 2024
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Barbara Brannetti, Jennifer Brogdon, Boris Engels, Brian Granda, Lu Huang, Ming Lei, Na Li, Jimin Zhang, Carla Guimaraes, Saar Gill, Marco Ruella, Regina M. Young